EC Number   |
Inhibitors |
Structure  |
|---|
   3.4.24.23 | more |
not: phosphoramidon; Zincov |
 |
| 3.4.24.23 | more |
examination of inhibitor-enzyme complexes emphasizes the dominant role the zinc-coordination group plays in determining the relative potencies of their inhibitors |
|
| 3.4.24.23 | more |
two zinc and two calciums are required for inhibitor binding |
|
| 3.4.24.23 | more |
no inhibition with phosphoramidon |
|
| 3.4.24.23 | more |
for lignans, dibenzylbutyryrolactone structure is essential for inhibitory effect |
|
| 3.4.24.23 | more |
estrogen acidification of the luminal solution tends to alkalinize exocytotic vesicles and may lead to decreased activation of the MMP-7 |
|
| 3.4.24.23 | more |
MMP-7 interacts with anionic, cationic and neutral lipid membranes, while the catalytic activity of the enzyme remains unaffected upon binding to neutral and negatively charged membranes, it is drastically impaired upon binding to the positively charged membranes, overview |
|
| 3.4.24.23 | more |
angiogenesis and apoptosis do not influence MMP-7 expression in lung cancer cells, overview |
|
| 3.4.24.23 | more |
inhibition of hyaluronan synthases HAS2 and HAS3 highly decreases MMP-7 expression and activity in SW620 cells |
|
| 3.4.24.23 | more |
MMP-7 knockout or inhibition retards cleavage of N-cadherin and vascular smooth muscle cell apoptosis, overview |
|
